FindTrial
Sign In

Clinical investigation for combination therapy of KAD-1229 and Pioglitazone.

Clinical investigation for combination therapy of KAD-1229 and Pioglitazone.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220136
Enrollment
Unknown
Registered
2005-10-03
Start date
2005-10-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

investigational material(s) Generic name etc : KAD-1229 (mitiglinide) INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigation

Sponsors

KISSEI PHARMACEUTICAL CO.,LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Main Inclusion Criteria: - Type 2 diabetic outpatients, aged 20 years or older, who are treated with diet and stable dose of pioglitazone monotherapy. - HbA1c and post prandial glucose are within a certain range Main Exclusion Criteria: - Patients who require treatment with insulin. - Patients complicated with severe diabetic microangiopathy (neuropathy, retinopathy or nephropathy). - Patients complicated with severe cardiac disease, hepatic disease, renal disease or hypertension.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy, Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026